THE UK PHARMACEUTICAL PRICE REGULATION SCHEME (PPRS) – CONSIDERATIONS OF VOLUNTARY VERSUS STATUTORY REGULATIONS AND HOW TO NEGOTIATE PRICING
Author(s)
Hill CA, Harries M
MAP BioPharma Limited, Cambridge, UK
Presentation Documents
OBJECTIVES: The UK operates free pricing of new chemical entities (NCEs). The 2014 PPRS was a radical departure from its predecessors, focussing on industry’s obligation to repay the Department of Health (DH) for growth in the NHS drug expenditure beyond certain limits. These repayments look set to exceed original estimates, reducing certainty for members of the voluntary scheme. The statutory regulations impose higher price cuts at the outset, ensuring those not in the PPRS do not have an advantage. As NHS sales from new NCEs launched after Jan 1st
Conference/Value in Health Info
2015-11, ISPOR Europe 2015, Milan, Italy
Value in Health, Vol. 18, No. 7 (November 2015)
Code
PHP34
Topic
Economic Evaluation, Health Policy & Regulatory
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies, Health Disparities & Equity, Pricing Policy & Schemes, Reimbursement & Access Policy
Disease
Multiple Diseases